Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy

The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent... Nucl Med Mol Imaging (2014) 48:130–136 DOI 10.1007/s13139-013-0248-y ORIGINAL ARTICLE The Role of F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy Jiyoun Choi & Hyun Jeong Kim & Yong Hyu Jeong & Jae-Hoon Lee & Arthur Cho & Mijin Yun & Jong Doo Lee & Yong Bae Kim & Young Tae Kim & Won Jun Kang Received: 1 July 2013 /Revised: 16 October 2013 /Accepted: 22 October 2013 /Published online: 15 November 2013 Korean Society of Nuclear Medicine 2013 Abstract Results Of 136 patients, 124 showed complete response on Purpose To determine whether persisting cervical further follow-up studies and 12 were confirmed to have fluorodeoxyglucose (FDG) uptake after concurrent chemora- residual tumor. The post-treatment SUVmax and pre-/post- diotherapy (CCRT) for cervical cancer can reflect residual treatment SUVmean of complete responders were significant- malignancy. ly lower than those of patients with residual tumor: 2.5±0.8 Methods F-FDG PET/CT was performed before and after and 7.2±4.2/1.9±0.7 for complete responders and 5.7±2.6 CCRT in 136 patients with cervical cancer. The maximum and 12.8±6.9/3.7±0.7 for patients with residual tumor (p < and mean standardized uptake values (SUVmax and 0.05). The pre-treatment SUVmax and pre-/post-treatment SUVmean) were recorded from PET/CT http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nuclear Medicine and Molecular Imaging Springer Journals

The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/the-role-of-18-f-fdg-pet-ct-in-assessing-therapy-response-in-cervix-700BDku2y4

References (31)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Korean Society of Nuclear Medicine
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1869-3474
eISSN
1869-3482
DOI
10.1007/s13139-013-0248-y
pmid
24900153
Publisher site
See Article on Publisher Site

Abstract

Nucl Med Mol Imaging (2014) 48:130–136 DOI 10.1007/s13139-013-0248-y ORIGINAL ARTICLE The Role of F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy Jiyoun Choi & Hyun Jeong Kim & Yong Hyu Jeong & Jae-Hoon Lee & Arthur Cho & Mijin Yun & Jong Doo Lee & Yong Bae Kim & Young Tae Kim & Won Jun Kang Received: 1 July 2013 /Revised: 16 October 2013 /Accepted: 22 October 2013 /Published online: 15 November 2013 Korean Society of Nuclear Medicine 2013 Abstract Results Of 136 patients, 124 showed complete response on Purpose To determine whether persisting cervical further follow-up studies and 12 were confirmed to have fluorodeoxyglucose (FDG) uptake after concurrent chemora- residual tumor. The post-treatment SUVmax and pre-/post- diotherapy (CCRT) for cervical cancer can reflect residual treatment SUVmean of complete responders were significant- malignancy. ly lower than those of patients with residual tumor: 2.5±0.8 Methods F-FDG PET/CT was performed before and after and 7.2±4.2/1.9±0.7 for complete responders and 5.7±2.6 CCRT in 136 patients with cervical cancer. The maximum and 12.8±6.9/3.7±0.7 for patients with residual tumor (p < and mean standardized uptake values (SUVmax and 0.05). The pre-treatment SUVmax and pre-/post-treatment SUVmean) were recorded from PET/CT

Journal

Nuclear Medicine and Molecular Imaging – Springer Journals

Published: Nov 15, 2013

There are no references for this article.